1h Free Analyst Time
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.Speak directly to the analyst to clarify any post sales queries you may have.
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 2 respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Gastrointestinal, Hematological Disorders, Immunology, Toxicology and Women's Health which include indications Coronavirus Disease 2019 (COVID-19), Non-Small Cell Lung Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia Areata, Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Cervical Intraepithelial Neoplasia (CIN), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Esophageal Cancer, Follicular Lymphoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Idiopathic CD4 Lymphocytopenia, Kaposi Sarcoma, Laryngeal Cancer, Lymphocytopenia, Malignant Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycobacterium avium Infections, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sjogren's Syndrome, Progressive Multifocal Leukoencephalopathy, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sepsis, Sezary Syndrome, Small-Cell Lung Cancer, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC) and Ulcerative Colitis.
The latest report Interleukin 7 Receptor Subunit Alpha - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
- The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development
- Allterum Therapeutics LLC
- Genexine Inc
- Medikine Inc
- OSE Immunotherapeutics SA
- RevImmune SAS
- Zura Bio Ltd
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles
- CYT-107 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- efineptakin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lusvertikimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MDK-701 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Antagonize IL7R for Acute Lymphocytic Leukemia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OSE-703 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ZB-168 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products
- Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Indications, 2022 (Contd..2)
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Companies, 2022 (Contd..3)
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Allterum Therapeutics LLC, 2022
- Pipeline by Genexine Inc, 2022
- Pipeline by Medikine Inc, 2022
- Pipeline by OSE Immunotherapeutics SA, 2022
- Pipeline by RevImmune SAS, 2022
- Pipeline by Zura Bio Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allterum Therapeutics LLC
- Genexine Inc
- Medikine Inc
- OSE Immunotherapeutics SA
- RevImmune SAS
- Zura Bio Ltd
